Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 651879, 12 pages
http://dx.doi.org/10.1155/2015/651879
Review Article

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

1Lahey Hospital & Medical Center, 41 Mall Road, Burlington, MA 01805, USA
2Institut Multidisciplinaire d’Oncologie, Clinique de Genolier, Case Postale 100, Route du Muids 3, 1272 Genolier, Switzerland
3Department of Internal Medicine IV, Hematology/Oncology, Martin-Luther-University Halle/Wittenberg, Ernst-Grube-Straße 40, 06120 Halle, Germany
4The West Clinic, 100 Humphreys Boulevard, Memphis, TN 38120, USA
5Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia
6University of California San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, P.O. Box 1710, San Francisco, CA 94115, USA

Received 18 November 2014; Revised 20 February 2015; Accepted 25 February 2015

Academic Editor: Min Li

Copyright © 2015 Paul J. Hesketh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. G. Frame, “Best practice management of CINV in oncology patients: I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches,” The Journal of Supportive Oncology, vol. 8, no. 2, supplement 1, pp. 5–9, 2010. View at Google Scholar · View at Scopus
  2. P. Feyer and K. Jordan, “Update and new trends in antiemetic therapy: the continuing need for novel therapies,” Annals of Oncology, vol. 22, no. 1, pp. 30–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Roila, J. Herrstedt, M. Aapro et al., “Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference,” Annals of Oncology, vol. 21, no. 5, pp. v232–v243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Basch, A. A. Prestrud, P. J. Hesketh et al., “Antiemetics: American Society of Clinical Oncology clinical practice guideline update,” Journal of Clinical Oncology, vol. 29, no. 31, pp. 4189–4198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Antiemesis Version 1, 2014, http://www.nccn.org/.
  6. M. Aapro, A. Molassiotis, M. Dicato et al., “The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER),” Annals of Oncology, vol. 23, no. 8, pp. 1986–1992, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. W. Gilmore, N. W. Peacock, A. Gu et al., “Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study,” Journal of Oncology Practice, vol. 10, no. 1, pp. 68–74, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Burmeister, S. Aebi, C. Studer, M. F. Fey, and O. Gautschi, “Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting,” Supportive Care in Cancer, vol. 20, no. 1, pp. 141–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Tendas, F. Sollazzo, P. Niscola et al., “Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score,” Supportive Care in Cancer, vol. 21, no. 1, pp. 5–6, 2013. View at Publisher · View at Google Scholar
  10. C. Rojas, M. Raje, T. Tsukamoto, and B. S. Slusher, “Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis,” European Journal of Pharmacology, vol. 722, no. 1, pp. 26–37, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Stathis, C. Pietra, C. Rojas, and B. S. Slusher, “Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects,” European Journal of Pharmacology, vol. 689, no. 1–3, pp. 25–30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Gralla, M. Lichinitser, S. van der Vegt et al., “Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron,” Annals of Oncology, vol. 14, no. 10, pp. 1570–1577, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Saito, K. Aogi, I. Sekine et al., “Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial,” The Lancet Oncology, vol. 10, no. 2, pp. 115–124, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. S. Aapro, S. M. Grunberg, G. M. Manikhas et al., “A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy,” Annals of Oncology, vol. 17, no. 9, pp. 1441–1449, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Jordan, C. Sippel, and H.-J. Schmoll, “Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations,” The Oncologist, vol. 12, no. 9, pp. 1143–1150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Jordan, R. Gralla, F. Jahn, and A. Molassiotis, “International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice,” European Journal of Pharmacology, vol. 722, no. 1, pp. 197–202, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Jordan, I. Kinitz, W. Voigt, T. Behlendorf, H.-H. Wolf, and H.-J. Schmoll, “Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy,” European Journal of Cancer, vol. 45, no. 7, pp. 1184–1187, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. V. dos Santos and J. P. Lima, “Important clinical findings for chemotherapy-induced nausea and vomiting: commentary on molassiotis et al,” Journal of Pain and Symptom Management, vol. 47, no. 5, article 827, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Schmidt, C. Ricarte, and G. Haas, “Evaluation of treatment patterns in acute nausea and vomiting in EU5 countries,” Annals of Oncology, vol. 25, no. 4, p. iv480, 2014. View at Publisher · View at Google Scholar
  20. S. M. Grunberg, “Obstacles to the implementation of antiemetic guidelines,” Journal of the National Comprehensive Cancer Network, vol. 7, no. 5, pp. 601–605, 2009. View at Google Scholar · View at Scopus
  21. R. Kaiser, “Antiemetic guidelines: are they being used?” The Lancet Oncology, vol. 6, no. 8, pp. 622–625, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. D. Cabana, C. S. Rand, N. R. Powe et al., “Why don’t physicians follow clinical practice guidelines? A framework for improvement,” The Journal of the American Medical Association, vol. 282, no. 15, pp. 1458–1465, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. W. C. Mertens, D. J. Higby, D. Brown et al., “Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines,” Journal of Clinical Oncology, vol. 21, no. 7, pp. 1373–1378, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Dranitsaris, P. Leung, and D. Warr, “Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study,” Supportive Care in Cancer, vol. 9, no. 8, pp. 611–618, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. M. J. Nolte, R. Berkery, B. Pizzo et al., “Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center,” Journal of Clinical Oncology, vol. 16, no. 2, pp. 771–778, 1998. View at Google Scholar · View at Scopus
  26. F. Roila, “Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions,” Supportive Care in Cancer, vol. 12, no. 6, pp. 446–453, 2004. View at Publisher · View at Google Scholar
  27. T. Spinelli, S. Calcagnile, C. Giuliano et al., “Netupitant PET imaging and ADME studies in humans,” Journal of Clinical Pharmacology, vol. 54, no. 1, pp. 97–108, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. A. G. Thomas, M. Stathis, C. Rojas, and B. S. Slusher, “Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells,” Experimental Brain Research, vol. 232, no. 8, pp. 2637–2644, 2014. View at Publisher · View at Google Scholar
  29. S. Calcagnile, C. Lanzarotti, G. Rossi, A. Henriksson, K. P. Kammerer, and W. Timmer, “Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives,” Supportive Care in Cancer, vol. 21, no. 10, pp. 2879–2887, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Lanzarotti and G. Rossi, “Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone,” Supportive Care in Cancer, vol. 21, no. 10, pp. 2783–2791, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Giuliano, E. Lovati, C. Funk et al., “In vitro drug-drug interaction studies with the antiemetic drug netupitant and its major metabolites (M1 and M2), involving main human cytochrome P450 isoenzymes,” Annals of Oncology, vol. 23, no. 9, pp. ix499–ix527, 2012, (abstract 1618). View at Publisher · View at Google Scholar
  32. M. S. Aapro and C. M. Walko, “Aprepitant: drug-drug interactions in perspective,” Annals of Oncology, vol. 21, no. 12, pp. 2316–2323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. P. J. Hesketh, G. Rossi, G. Rizzi et al., “Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study,” Annals of Oncology, vol. 25, no. 7, pp. 1340–1346, 2014. View at Publisher · View at Google Scholar
  34. M. Aapro, H. Rugo, G. Rossi et al., “A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy,” Annals of Oncology, vol. 25, no. 7, pp. 1328–1333, 2014. View at Publisher · View at Google Scholar
  35. R. J. Gralla, S. M. Bosnjak, A. Hontsa et al., “A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy,” Annals of Oncology, vol. 25, no. 7, pp. 1333–1339, 2014. View at Publisher · View at Google Scholar
  36. Aloxi (palonosetron HCl) soft capsules, summary of product characteristics, 2014.
  37. M. Aapro, R. Gralla, M. Karthaus et al., “Multicycle efficacy and safety of NEPA, a fixed-dose antiemetic combination of netupitant and palonosetron, in patients receiving chemotherapy of varying emetogenicity,” Annals of Oncology, vol. 25, no. 4, pp. iv518–iv519, 2014. View at Google Scholar
  38. National Institutes of Health, ClinicalTrials.gov, NCT01363479, September 2014.
  39. P. J. Hesketh, K. Jordan, and R. Gralla, “Prevention of chemotherapy-induced nausea and vomiting with a fixed-dose combination of netupitant and palonosetron (NEPA) following highly emetogenic chemotherapy: evaluation of response based on gender and age,” Annals of Oncology, vol. 25, supplement 4, pp. iv517–iv541, 2014. View at Publisher · View at Google Scholar
  40. C. M. Sheehy, P. A. Perry, and S. L. Cromwell, “Dehydration: biological considerations, age-related changes, and risk factors in older adults,” Biological Research for Nursing, vol. 1, no. 1, pp. 30–37, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Manson and S. Shea, “Malnutrition in elderly ambulatory medical patients,” American Journal of Public Health, vol. 81, no. 9, pp. 1195–1197, 1991. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Aapro, P. J. Hesketh, R. J. Gralla, K. Jordan, and G. Rizzi, “Safety and efficacy of NEPA, a fixed oral dose combination of netupitant and palonosetron, in older patients,” Journal of Geriatric Oncology, vol. 5, supplement 2, p. S72, 2014. View at Publisher · View at Google Scholar
  43. R. J. Gralla, R. de Wit, J. Herrstedt et al., “Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials,” Cancer, vol. 104, no. 4, pp. 864–868, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. P. J. Hesketh, R. Gralla, G. Rossi et al., “NEPA, a fixed-dose antiemetic combination of netupitant and palonosetron: results of effectiveness in 407 patients receiving cisplatin plus chemotherapy of various emetic risk,” Support Care Cancer, vol. 22, no. 1, abstract 0159, pp. S1–S238, 2014. View at Google Scholar
  45. K. Jordan, R. Gralla, G. Rossi et al., “Is the addition of an NK1 receptor antagonist beneficial in patients receiving carboplatin? Supplementary data with NEPA, a fixed-dose combination of netupitant and palonosetron,” Supportive Care in Cancer, vol. 22, no. 1, pp. S1–S238, 2014. View at Google Scholar
  46. M. Aapro, M. Karthaus, L. Schwartzberg et al., “Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles,” Journal of Clinical Oncology, vol. 32, no. 15, article 9502, 2014. View at Google Scholar
  47. M. Aapro, P. J. Hesketh, K. Jordan et al., “Safety of NEPA, an oral fixed-dose combination of netupitant and palonosetron: pooled data from the phase 2/3 clinical program,” Support Care Cancer, vol. 22, no. 1, pp. S1–S238, 2014, (Abstract no. 0158). View at Google Scholar
  48. J. Morganroth, S. Parisi, C. Moresino, M. Thorn, and M. T. Cullen, “High dose palonosetron does not alter ECG parameters, including QTc interval in healthy subjects: results of a dose-response, double blind, randomized, parallel El4 study of palonosetron vs. moxifloxacin or placebo,” European Journal of Cancer Supplements, vol. 5, no. 4, pp. 158–159, 2007, (Abstract No. 1156). View at Publisher · View at Google Scholar
  49. T. Spinelli, C. Moresino, S. Baumann, W. Timmer, and A. Schultz, “Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial,” SpringerPlus, vol. 3, article 389, 2014. View at Publisher · View at Google Scholar
  50. G. Gonullu, S. Demircan, M. K. Demirag, D. Erdem, and I. Yucel, “Electrocardiographic findings of palonosetron in cancer patients,” Supportive Care in Cancer, vol. 20, no. 7, pp. 1435–1439, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Yavas, U. Dogan, G. Yavas, M. Araz, and O. Yavas Ata, “Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study,” Supportive Care in Cancer, vol. 20, no. 10, pp. 2343–2347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. U. Dogan, G. Yavas, M. Tekinalp, C. Yavas, O. Y. Ata, and K. Ozdemir, “Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization,” European Review for Medical and Pharmacological Sciences, vol. 16, no. 4, pp. 462–468, 2012. View at Google Scholar · View at Scopus
  53. B. L. Rapoport, K. Jordan, J. A. Boice et al., “Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study,” Supportive Care in Cancer, vol. 18, no. 4, pp. 423–431, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. D. G. Warr, P. J. Hesketh, R. J. Gralla et al., “Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2822–2830, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Poli-Bigelli, J. Rodrigues-Pereira, A. D. Carides et al., “Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America,” Cancer, vol. 97, no. 12, pp. 3090–3098, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. P. J. Hesketh, S. M. Grunberg, R. J. Gralla et al., “The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group,” Journal of Clinical Oncology, vol. 21, no. 22, pp. 4112–4119, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. H. J. Schmoll, M. S. Aapro, S. Poli-Bigelli et al., “Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment,” Annals of Oncology, vol. 17, no. 6, pp. 1000–1006, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. B. L. Rapoport, “Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region,” Current Medical Research and Opinion, vol. 30, no. 9, pp. 1875–1881, 2014. View at Publisher · View at Google Scholar
  59. R. Gralla, B. Rapoport, C. Brown, J. C. Street, J. S. Hardwick, and A. D. Carides, “57LBA Aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) in breast and non-breast cancers,” European Journal of Cancer Supplements, vol. 7, no. 3, pp. 23–24, 2009. View at Publisher · View at Google Scholar
  60. H. Yahata, K. Sonoda, H. Kobayashi et al., “Aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy: a multicenter, placebo-controlled, double-blind, randomized study in Japanese gynecologic patients receiving paclitaxel and carboplatin,” Annals of Oncology, vol. 25, no. 4, pp. iv517–iv541, 2014. View at Google Scholar
  61. I. Schnadig, M. R. Modiano, A. Poma et al., “Phase 3 trial results for rolapitant, a novel, NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC),” Journal of Clinical Oncology, vol. 32, supplement 5, abstract 9633, 2014. View at Google Scholar
  62. US Food and Drug Administration (FDA), FDA Drug Safety Communication: Abnormal Heart Rhythms May Be Associated with Use of Zofran (Ondansetron), FDA, Silver Spring, Md, USA, 2011, http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm.
  63. Food and Drug Administration, FDA Drug Safety Communication: Abnormal Heart Rhythms Associated with Use of Anzemet (Dolasetron Mesylate), FDA, Silver Spring, Md, USA, 2010, http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm.
  64. FDA Safety, Kytril (Granisetron Hydrochloride) Injection, Tablets and Oral Solution, FDA, Silver Spring, MD, USA, 2009, http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm187526.htm.
  65. L. Schwartzberg, C. Oprean, S. Cardona-Huerta et al., “No evidence of increased cyclophosphamide toxicity associated with the antiemetic agent NEPA, a fixed-dose combination of netupitant and palonosetron,” Blood, vol. 122, no. 21, p. 2949, 2013. View at Google Scholar
  66. M. Karthaus, M. Aapro, G. Rizzi et al., “Cardiac safety of NEPA, a fixed-dose antiemetic combination, administered prior to anthracycline-based chemotherapy,” Blood, vol. 124, abstract 4821, 2014. View at Google Scholar